Comparison · NCT01654445-4222c77d
Tenecteplase 0.1 mg/kg vs Tenecteplase 0.25 mg/kg: Number of Patients With Serious Bleeding Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tenecteplase 0.1 mg/kg vs Tenecteplase 0.25 mg/kg: Number of Patients With Serious Bleeding Events. Trial comparisons, record NCT01654445-4222c77d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01654445-4222c77d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0.0000000000000000139 | 0.133 | wilson | |
| Risk in group 2 | 0.04 | 0.0071 | 0.195 | wilson | |
| Risk difference, group 1 minus group 2 | -0.04 | -0.195 | 0.0972 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Tenecteplase 0.1 mg/kg than on Tenecteplase 0.25 mg/kg | 25 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tenecteplase 0.1 mg/kg | 25 patients treated with 0.1 mg/kg intravenous tenecteplase | 0 | 25 | OG000 |
| Group 2 | Tenecteplase 0.25 mg/kg | 25 patients treated with 0.25 mg/kg intravenous tenecteplase | 1 | 25 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Patients With Serious Bleeding Events
- Description
The primary safety outcome will be the rate of expected serious adverse events associated with study drug. This will be defined as the number patients with at least one SAE divided by the number of patients enrolled by dose-tier. Thus, the unit of analysis will be the patient and not the SAE.
- Time frame
- Up to 12 weeks
- Population
- All participants
Source ClinicalTrials.gov
Trial
- Title
- TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion
- NCT number
- NCT01654445
- Phases
- PHASE2
- Conditions
- Ischemic Stroke
- Interventions
- Tenecteplase
- Lead sponsor
- University of Calgary
- Results first posted
- 2020-11-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01654445?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01654445-4222c77d